Human IL-21 Platinum ELISA

Description: The human IL-21 ELISA is an enzyme-linked immunosorbent assay for the quantitative detection of human IL-21. The human IL-21 ELISA is for research use only. Not for diagnostic or therapeutic procedures.

Interleukin-21 is a member of the type-I cytokine family. Structurally, IL-21 shows homology to IL-2, IL-4, and IL-15 proteins. IL-21 shares the common gamma-chain with these three cytokines, but, in addition, binds to a unique IL-21R alpha chain, and activates the JAK/STAT pathway.

IL-21 has pleiotropic actions, from augmenting the proliferation of T cells and driving the differentiation of B cells into memory cells and terminally differentiated plasma cells to augmenting the activity of natural killer cells. IL-21 is mainly produced by activated T-cells, but targets a broad range of lymphoid and myeloid cells of the immune system and therefore is able to regulate innate and acquired immune responses. IL-21 has pathologic function in immune-inflammatory diseases. Data suggest the existence of a positive autocrine loop that could help to amplify and stabilize IL-21-driven, T cell-mediated responses. Moreover, it has antitumour activity and may have a role in the development of autoimmunity. IL-21 may have therapeutic potentials as an antitumor agent in the clinic.

References: Pelletier,M.; Bouchard,A.; Girard,D.. In vivo and in vitro roles of IL-21 in inflammation. J Immunol 2004;173:7521-7530. (Link)

Leonard,W.J.; Spolski,R.. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev.Immunol 2005;5:688-698. (Link)

Onoda,T.; Rahman,M.; Nara,H.; Araki,A.; Makabe,K.; Tsumoto,K.; Kumagai,I.; Kudo,T.; Ishii,N.; Tanaka,N.; Sugamura,K.; Hayasaka,K.; Asao,H.. Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets. Int Immunol 2007;19:1191-1199. (Link)

Cappuccio,A.; Elishmereni,M.; Agur,Z.. Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 2006;66:7293-7300. (Link)

Brandt,K.; Singh,P.B.; Bulfone-Paus,S.; Ruckert,R.. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 2007;18:223-232. (Link)

Peluso,I.; Fantini,M.C.; Fina,D.; Caruso,R.; Boirivant,M.; MacDonald,T.T.; Pallone,F.; Monteleone,G.. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 2007;178:732-739. (Link)

Alves,N.L.; Arosa,F.A.; van Lier,R.A.. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J Immunol 2005;175:755-762. (Link)

Konforte,D.; Paige,C.J.. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J Immunol 2006;177:8381-8392. (Link)

Parrish-Novak,J.; Foster,D.C.; Holly,R.D.; Clegg,C.H.. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc.Biol 2002;72:856-863. (Link)

Wang,G.; Tschoi,M.; Spolski,R.; Lou,Y.; Ozaki,K.; Feng,C.; Kim,G.; Leonard,W.J.; Hwu,P.. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003;63:9016-9022. (Link)

Monteleone,G.; Caruso,R.; Fina,D.; Peluso,I.; Gioia,V.; Stolfi,C.; Fantini,M.C.; Caprioli,F.; Tersigni,R.; Alessandroni,L.; MacDonald,T.T.; Pallone,F.. Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006;55:1774-1780. (Link)

Caprioli,F.; Sarra,M.; Caruso,R.; Stolfi,C.; Fina,D.; Sica,G.; MacDonald,T.T.; Pallone,F.; Monteleone,G.. Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 2008;180:1800-1807. (Link)